Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 1 chart position in 1 market.
By chart position
- 🇲🇾MY · Medicine#111500 to 3K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
250 to 1.5K🎙 Weekly cadence·50 episodes·Last published yesterday - Monthly Reach
Unique listeners across all episodes (30 days)
500 to 3K🇲🇾100% - Active Followers
Loyal subscribers who consistently listen
150 to 900
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 10 epsHosts
Recent guests
Recent episodes
Fabio Efficace and Alice Di Rocco on patient-reported outcomes following CAR T-cell therapy
Jul 3, 2026
15m 55s
Carmelo Gurnari on the development of recommendations from the EBMT Practice Harmonisation and Guidelines Committee
Jun 4, 2026
17m 05s
Penelope Stein on acute prophyria
Apr 28, 2026
16m 01s
Marc Riedl on hereditary angioedema
Apr 2, 2026
17m 30s
Julio Delgado and Valentín Ortiz-Maldonado (Spanish version)
Mar 4, 2026
12m 55s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 7/3/26 |  Fabio Efficace and Alice Di Rocco on patient-reported outcomes following CAR T-cell therapy | Most previous patient-reported outcome results for CAR T-cell therapy have come from clinical trials testing these treatments, but information on how patients experience this treatment in real-world settings is scarce. Dr Fabio Efficace and Dr Alice Di Rocco discuss their recent prospective study to measure real-world patient-reported symtomatic adverse events in those receiving CAR T-cell therapy for aggressive B-cell lymphomas, and how these outcomes match those reported by the physicans treating the patients. They discuss some of the rich and varied findings that they uncovered from their study. Click here to read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00128-6/fulltext The Lancet Haematology in conversation with... is part of the Lancet Group podcast offering. Editorial team: editor-in-chief Lan-Lan Smith, deputy editor Emma Cookson, and senior editor Daniela Marin Podcast editing: Matteo Simonetti Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering. Find the best science for better lives at www.thelancet.comFollow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv | 15m 55s | ||||||
| 6/4/26 | Carmelo Gurnari on the development of recommendations from the EBMT Practice Harmonisation and Guidelines Committee✨ | haematological neoplasmsHCT+3 | Carmelo Gurnari | EBMT Practice Harmonisation and Guidelines CommitteeThe Lancet Group+1 | — | haematologyEBMT+3 | — | 17m 05s | |
| 4/28/26 | Penelope Stein on acute prophyria✨ | acute prophyriagenetic conditions+4 | Dr Penelope Stein | The Lancet | — | acute prophyriaguidelines+4 | — | 16m 01s | |
| 4/2/26 | Marc Riedl on hereditary angioedema✨ | hereditary angioedemadeucrictibant+3 | Marc Riedl | deucrictibantThe Lancet | — | hereditary angioedemadeucrictibant+3 | — | 17m 30s | |
| 3/4/26 | Julio Delgado and Valentín Ortiz-Maldonado (Spanish version)✨ | B-cell precursor acute lymphoblastic leukaemiaclinical trials+3 | Dr Julio DelgadoDr Valentín Ortiz-Maldonado | varnimcabtagene autoleucelThe Lancet+1 | Spain | varnimcabtagene autoleucelB-cell precursor acute lymphoblastic leukaemia+3 | — | 12m 55s | |
| 3/4/26 | Julio Delgado and Valentín Ortiz-Maldonado✨ | clinical trialsleukemia treatment+3 | Dr Julio DelgadoDr Valentín Ortiz-Maldonado | The Lancet Groupvarnimcabtagene autoleucel+1 | Spain | varnimcabtagene autoleucelacute lymphoblastic leukaemia+3 | — | 12m 04s | |
| 2/4/26 | Erica Kaye and Dylan Graetz discuss expert recommendations for the conduct and appraisal of qualitative research in haematology✨ | qualitative researchhaematology+3 | Dr Erica KayeDr Dylan Graetz | The Lancet | — | qualitative researchhaematology+3 | — | 19m 40s | |
| 12/31/25 | Presented at ASH: API-CAT post-hoc analysis on predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated VTE✨ | anticoagulationcancer-associated VTE+3 | Professor Isabelle Mahé | The Lancet GroupAPI-CAT+2 | — | anticoagulationcancer+5 | — | 9m 55s | |
| 12/8/25 | Presented at ASH 2025: EPCORE CLL-1 trial on epcoritamab monotherapy for Richter transformation✨ | CLLepcoritamab+4 | Arnon Kater | epcoritamabThe Lancet Haematology+1 | — | epcoritamabRichter transformation+5 | — | 14m 22s | |
| 12/2/25 | ASH 2025 Preview - Expert Roundtable✨ | haematologyASH 2025+3 | Khaled MusallamBethany Samuelson Bannow+3 | The Lancet Group | Orlando | ASH 2025haematology+3 | — | 22m 12s | |
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 12/1/25 | Arnon Kater and Sabina Kersting on the HOVON 158/NEXT STEP phase 2 trial testing a new first-line treatment regimen for chronic lymphocytic leukaemia✨ | chronic lymphocytic leukaemiatreatment regimen+4 | Arnon KaterSabina Kersting | HOVONibrutinib+3 | — | chronic lymphocytic leukaemiaHOVON 158+5 | — | 24m 24s | |
| 11/3/25 | Ruben Mesa on ropeginterferon alfa-2b for hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia | Dr. Ruben Mesa (Executive Director of the Wake Forest Baptist Comprehensive Cancer Center) joins us to discuss the results of a multicentre, open-label, randomised, active-controlled, phase 3 study of ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia. Click here to read the full article Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelanc... | 11m 45s | ||||||
| 9/14/25 | A panel of the authors on our Lancet Haematology-Lancet Regional Health Western Pacific Series on mature T-cell and natural killer-cell lymphomas | Today, on World Lymphoma Awareness Day, Professors Yok Lam Kwong, Wee Joo Chng, and Eric Tse join us in this joint episode of The Lancet Haematology and The Lancet Regional Health - Western Pacific to discuss their recent Series on advances in genomic techniques that have transformed the diagnosis, prognosis, and targeted treatment of mature T-cell and natural killer-cell lymphoma. Read the Series: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00228-5/?dgcid=buzzsprout_ic... | 17m 58s | ||||||
| 8/4/25 | Lan-Lan Smith, Cheryl Lai, and Daniela Marín discuss the EHA, ICML, and ISTH conferences | June has been packed with interesting haematology conferences so the editorial team behind The Lancet Haematology have gathered to share their thoughts and reflect on their experiences at the European Hematology Association, International Conference on Malignant Lymphoma, and International Society on Thrombosis and Haemostasis meetings. Read our conference round-ups here: EHA: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00206-6/fulltext?dgcid=buzzsprout_icw_podcast_Augu... | 19m 10s | ||||||
| 7/1/25 | Paolo Strati on off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy for patients with relapsed or refractory B-cell lympho... | Associate Professor Paolo Strati (Department of Lymphoma and Myeloma, and Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA) joins us to discuss the results of a multicentre, open-label, phase 1 clinical trial of off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy for patients with relapsed or refractory B-cell lymphoma. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3... | 21m 49s | ||||||
| 6/13/25 | A panel of the authors on our Adverse Events Series on adverse event reporting in haematological malignancies | With a growing number of treatment options for blood cancers, understanding the side effects from these treatments and how they affect patients is becoming ever more important. Join a panel of authors from The Lancet Haematology's latest series on Adverse Event reporting to discuss how we can improve clinical trial design and analysis, and translate this data to meaningful, patient-centric care. Read the full series here: https://www.thelancet.com/series-do/adverse-events-in-haematology-oncol... | 40m 11s | ||||||
| 4/28/25 | Michael Northend on early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma | Dr Michael Northend (University College London Hospitals NHS Foundation Trust, and Cancer Research UK & UCL Cancer Trials Centre, London, UK) joins us to discuss the long-term results of a randomised, phase 3 trial on early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00034-1/fulltext?dgcid=buzzsprout_icw_podcast_28-04-25_lanha... | 15m 49s | ||||||
| 3/31/25 | Joanne Verweij and Romy Pothof on fetal and neonatal alloimmune thrombocytopenia | Dr Romy Pothof and Prof Joanne Verweij join us to discuss their development of an international consensus on the diagnosis and treatment of fetal and neonatal alloimmune thrombocytopenia. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00029-8/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancet... | 17m 47s | ||||||
| 3/3/25 | Helene Schoemans, Elke Stienissen, and Kathy Goris on a consulting a patient advisory board to understand unmet needs of patients with GVHD in Europe | Prof Helene Schoemans, Elke Stienissen, and Kathy Goris join us to discuss the importance of consulting a patient advisory board to understand unmet needs of patients with GVHD in Europe. Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv | 27m 06s | ||||||
| 1/29/25 | Dawn Swan on air pollution and venous thromboembolism | Dr Dawn Swan joins us to discuss current knowledge and future perspectives on the possible association between air pollution and venous thromboembolism. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00291-6/fulltext?dgcid=buzzsprout_icw_podcast_general_lanhae Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.co... | 15m 02s | ||||||
| 1/16/25 | Leslie Skeith on low-dose aspirin for postpartum venous thromboembolism prophylaxis | Dr Leslie Skeith joins us to discuss the PARTUM pilot trial, comparing low-dose aspirin versus placebo in postpartum venous thromboembolism. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00338-7/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/th... | 16m 03s | ||||||
| 12/3/24 | Neema Mayor and Caitlin Farrow on impact of patient ethnicity on haematopoeietic cell transplantation outcome in the United Kingdom | Dr Neema Mayor and Dr Caitlin Farrow from the Anthony Nolan Research Institute join us to discuss the findings of their study on the impact of patient ethnicity on haematopoietic cell transplantation outcomes in the United Kingdom. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00312-0/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/... | 17m 53s | ||||||
| 10/2/24 | Lancet Haematology 10 year anniversary - meet the editors | In a special 10 year anniversary podcast, Lan-Lan Smith, Yaiza del Pozo Martin, and Emma Cookson, the editorial team behind The Lancet Haematology, reflect on the last decade and give some insights into the editorial processes at The Lancet Group. Read our Editorial: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00289-8/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanhae Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://i... | 47m 21s | ||||||
| 8/22/24 | Matteo Della Porta on the phase 3 COMMANDS trial examining luspatercept versus epoetin alfa in patients with lower-risk myleodysplastic syndrome | Professor Matteo Giovanni Della Porta joins us to discuss the primary analysis of the phase 3 COMMANDS trial comparing luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndrome patients. Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/... | 8m 08s | ||||||
| 8/7/24 | Kim Linton on follicular lymphoma | Dr Kim Linton joins us to discuss the EPCORE NHL-1 trial testing monotherapy with the bispecific antibody epcoritamab for patients with relapsed or refractory follicular lymphoma. Read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00166-2?dgcid=buzzsprout_tlv_podcast_generic_lanhae Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal h... | 9m 48s | ||||||
Showing 25 of 53
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart Positions
1 placement across 1 market.
Chart Positions
1 placement across 1 market.